Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levobupivacaine + normal saline refers to the control intervention used in a clinical study by Cairo University evaluating postoperative analgesia. Levobupivacaine is a long-acting amide-type local anesthetic, specifically the S-enantiomer of bupivacaine. It works by inhibiting voltage-gated sodium channels in nerve membranes, which prevents the influx of sodium ions and the subsequent depolarization required for nerve impulse conduction. In the context of the Cairo University trial, this combination (19 ml of 0.5% levobupivacaine and 1 ml of 0.9% normal saline) is administered via ultrasound-guided spermatic cord block to manage postoperative pain in male patients undergoing testicular sperm extraction surgery. The saline component serves as a volume-matching control for the experimental adjuvant, neostigmine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levobupivacaine + normal saline.